PATHOZYME® PANCREATIC/GUT CANCER ANTIGEN 19-9 [Ref OD277] Enzyme Immunoassay for the quantitative determination of Gastrointestinal CA19-9 in human serum. Store at 2°C to 8°C. DO NOT FREEZE.

For in-vitro diagnostic use only.

INTRODUCTION
Pancreatic cancer accounts for approximately 2.3% of all cancers and the fourth most common cause of cancer deaths. The disease is more common in men than women with peak incidence occurring at age 60. CA 19-9 is the key marker for this disease.

CA 19-9 is a glycoprotein with a molecular weight of 100,000 Da. It is a derivative of the Lea blood group antigen present on normal gastrointestinal epithelium. Patients that are Lewis-a-/- do not synthesise CA19-9. Recent reports indicate that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease.

CA19-9 can also be elevated in non-malignant conditions such as chronic pancreatitis, cholangitis, cholercystitis and cirrhosis. For this reason the serum levels of CA19-9 should not be used in screening for pancreatic cancer but is of most use in the monitoring of the course of the disease and response to treatment.

INTENDED USE
PATHOZYME PANCREATIC/GUT CANCER ANTIGEN 19-9 is an Enzyme Immunoassay (EIA) for the quantitative determination of Gastrointestinal Cancer Antigen 19-9 in human serum.

For professional use only.

PRINCIPLE OF THE TEST
Specific monoclonal anti-Cancer Antigen 19-9 antibodies are coated on to microtitre wells. Test sera and Assay Buffer are added to the wells and incubated. The wells are then washed with water. Anti-Cancer Antigen 19-9 labelled with Horseradish Peroxidase enzyme (Conjugate) is added. If human Cancer Antigen 19-9 is present in the sample, it will combine with the antibody on the well and the enzyme Conjugate, resulting in the Cancer Antigen 19-9 molecules being sandwiched between the solid phase and the enzyme linked antibodies. After incubation, the wells are washed with distilled water to remove unbound labelled antibodies. On addition of the Substrate (TMB), a colour will develop only in those wells in which the enzyme is present, indicating the presence of Cancer Antigen 19-9. The enzyme reaction is stopped by the addition of Stop Solution and the absorbance is then measured at 450nm. The concentration of Cancer Antigen 19-9 is directly proportional to the colour intensity of the test sample.

This test has been calibrated against in house standards. There is no International standard for this test.

CONTENTS

MATERIALS REQUIRED BUT NOT PROVIDED
- Micropipettes: 100µl, 200µl and 1000µl
- Disposable pipette tips
- Incubator: Temperature of 37°C +/- 1°C
- Absorbance paper
- Microplate reader fitted with a 450nm filter
- Graph paper
- Thoroughly clean laboratory glassware.

PRECAUTIONS
PATHOZYME PANCREATIC/GUT CANCER ANTIGEN 19-9 reagents do not contain dangerous substances as defined by current UK Chemicals (Hazardous Information and Packaging for Supply) regulations. All reagents should, however, be treated as potentially hazardous in use and disposal. Final disposal must be in accordance with local legislation.

PATHOZYME PANCREATIC/GUT CANCER ANTIGEN 19-9 Stop Solution is a Hydrochloric Acid and is therefore corrosive. Handle with care. In case of contact, rinse thoroughly with water.

PATHOZYME PANCREATIC/GUT CANCER ANTIGEN 19-9 contains 1% ProClin™ 300® as a preservative which may be toxic if ingested. In case of contact, rinse thoroughly with running water and seek medical advice.

STORAGE
Reagents must be stored at temperatures between 2°C to 8°C.

Expiration date is the last day of the month on the bottle and the kit label. The kit will perform within specification until the stated expiry date as determined from date of product manufacture and stated on kit components. Do not use reagents after the expiry date.

Exposure of reagents to excessive temperatures should be avoided. Do not expose to direct sunlight.

DO NOT FREEZE ANY OF THE REAGENTS as this will cause irreversible damage.

SPECIMEN COLLECTION AND PREPARATION
Obtain a sample of venous blood from the patient and allow a clot to form and retract. Centrifuge clotted blood sample and collect clear serum. Fresh serum samples are required.

Do not use haemolysed, contaminated or lipemic serum for testing as this will adversely affect the results.

Serum may be stored at 2°C to 8°C for up to 48 hours prior to testing. If longer storage is required, store at –20°C for up to 1 year. Thawed samples must be mixed prior to testing.

Do not use Sodium Azide as a preservative as this may inhibit the Peroxidase enzyme system.

Do not repeatedly freeze-thaw the specimen as this will cause false results.

REAGENT PREPARATION
All reagents should be brought to room temperature (20°C to 25°C) and mixed gently prior to use. Do not induce foaming.

Working Solution: Dilute the concentrated conjugate using 1 part conjugate to 11 parts conjugate diluent (1:12 dilution). 100µl is required per well. Prepare fresh working solution for each assay performed.

LIMITATIONS OF USE
The use of samples other than serum has not been validated in this assay. There is no reuse protocol for this product.

When making an interpretation of the test it is strongly advised to take all clinical data into consideration. Diagnosis should not be made solely on the findings of one clinical assay.

MATERIAL REQUIRED BUT NOT PROVIDED
- Micropipettes: 100µl, 200µl and 1000µl
- Disposable pipette tips
- Incubator: Temperature of 37°C +/- 1°C
- Absorbance paper
- Microplate reader fitted with a 450nm filter
- Graph paper
- Thoroughly clean laboratory glassware.
ASSAY PROCEDURE

1. Bring all the kit components and the test serum to room temperature (20°C to 25°C) prior to the start of the assay.
2. One set of Standards should be run with each batch of test serum. Secure the desired number of coated wells in the holder. Record the position of the standards and the test serum on the EIA Data Recording Sheet provided.
3. Unused strips should be resealed in the foil bag containing the desiccant, using the resealing zip-lock before being replaced at 2°C to 8°C.
4. Dispense 10μl of Standards or test serum into the assigned wells.
5. Dispense 100μl of Assay Buffer into each well.
6. Thoroughly mix for 30 seconds. It is very important to have a complete mixing at this stage.
7. Incubate for 90 minutes at 37°C.
8. At the end of the incubation period, discard the contents of the wells by flicking plate contents into the Biohazard container. Then strike the wells sharply against absorbent paper. Ensure adequate decontamination is contained in the Biohazard container.
9. Hand Washing. Fill the wells with a minimum of 100μl of distilled water per well. Flick plate contents into a Biohazard container. Then strike the wells sharply against absorbent paper. Wash the empty wells 5 times.
10. Strike the wells sharply onto absorbent paper or paper towel to remove all residual water droplets.
11. Machine Washing: Ensure that 300μl of distilled water is dispersed per well and that an appropriate decontaminant is added to the wash collection bottle. Wash the empty wells 5 times. After washing remove excess fluid by striking the wells sharply onto absorbent paper or paper towel to remove all residual water droplets.
12. Dispense 100μl working strength Conjugate solution into each well and mix gently for 10 seconds.
13. Incubate for 90 minutes at 37°C.
14. Wash plate as above.
15. Dispense 100μl of Substrate Solution into each well and gently mix for 10 seconds.
16. Incubate in the dark for 90 minutes at room temperature (20°C to 25°C).
17. Stop the reaction by adding 100μl Stop Solution to each well.
18. Gently mix for 30 seconds to ensure that the blue colour changes completely to a yellow colour.
19. Read the optical density immediately (no later than 10 minutes) using a microplate reader with a 450nm filter.

TROUBLESHOOTING

For use by operatives with at least a minimum of basic laboratory training. Do not use damaged or contaminated kit components.

Use a separate disposable tip for each sample to prevent cross contamination.

Dilution of all standards and specimens, although not required, is recommended. Specimens and standards should be run at the same time to keep testing conditions the same. It is recommended that no more than 52 wells be used for each assay run if manual pipetting is used, since pipetting of all Standards and specimens should be completed within 3 minutes. A full plate of 96 wells may be used if automated pipetting is available.

Replace caps on all reagents immediately after use.

Avoid repeated pipetting from stock reagents as this is likely to cause contamination.

Do not mix reagents or antibody coated strips from different kits. When dispensing, care should be taken not to touch the surface of the well.

Do not allow reagent to run down the sides of the well. Prior to the start of the assay bring all reagents to room temperature (20°C to 25°C). Gently mix all reagents by gentle inversion or swirling.

Once an assay has been initiated, the wells should not be allowed to become dry during the assay.

The washing procedure is critical to the outcome of this test. Insufficient washing will result in poor precision and falsely elevated absorbance readings.

Do not contaminate the Substrate Solution as this will render the whole kit inoperative.

Check the precision and accuracy of the laboratory equipment used during the procedure to ensure reproducible results.

The unused strips should be resealed in the foil bag, containing the desiccant, using the resealing zip-lock before being replaced at 2°C to 8°C.

CALCULATION OF RESULTS

Calculate the mean absorbance value (Auo) for each set of Standards and specimens. Construct a standard curve by plotting the mean absorbance from each Standard against its concentration in Units on graph paper. Use the mean absorbance values for each specimen to determine the corresponding concentration of Pancreatic/Gut Cancer Antigen 19-9 in Units from the standard curve. If levels of controls or users known samples do not give expected results, test results must be considered invalid. If using a software package, choose a quadratic regression curve.

EXPECTED VALUES AND SENSITIVITY

The graph produced by the calibrators should be Hyperbolic in shape with the OD450 of the calibrators proportional to their concentration. The OD of calibrator A should be less than 0.5 and the OD of calibrator F greater than 1.2 for the assay results to be valid. Healthy men and women have normal expected Cancer Antigen 19-9 concentrations below 35 U/ml. The minimum detectable concentration of Cancer Antigen 19-9 by PATHOZYME PANCREATIC/GUT CANCER ANTIGEN 19-9 is estimated to be 10U/ml.

EVALUATION DATA

Calibrated to major competitors and in house standards. The co-efficient of variation of PATHOZYME PANCREATIC/GUT CANCER ANTIGEN 19-9 is less than or equal to 10%.

In an evaluation between the Omega Pathozyme CA 19-9 kit and the Abbott DIA. Kit for samples with levels between 1.4 Ul/ml and 207.4 Ul/ml the following data was generated.

<table>
<thead>
<tr>
<th>Number of samples</th>
<th>Correlation Co-efficient</th>
<th>Sample</th>
<th>Intercept</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>0.9313</td>
<td>1.00</td>
<td>6.77</td>
</tr>
</tbody>
</table>

Ωmega Mean 100.38 Ul/ml

Chromogen Mean 99.91 Ul/ml

These kits were shown to give good correlation.

REFERENCES


QUICK REFERENCE TEST PROCEDURE

1. Dispense 15μl of samples or Standards and 100μl of Assay Buffer into each well and gently mix for 30 seconds.
2. Incubate for 90 minutes at 37°C.
3. Discard the well contents and wash 5 times with distilled water.
4. Dispense 100μl of working strength Conjugate solution into each well and gently mix for 10 seconds.
5. Incubate for 90 minutes at 37°C.
6. Discard the well contents and wash 5 times with distilled water.
7. Add 10μl of Substrate Solution to each well. Gently mix for 10 seconds.
8. Incubate in the dark for 20 minutes at room temperature (20°C to 25°C).
9. Add 100μl of Stop Solution to each well and gently shake for 30 seconds.
10. Read Optical Densities immediately (no later than 10 minutes) using a microplate reader with a 450nm filter.